Details of the Drug

General Information of Drug (ID: DMDXTAE)

Drug Name

ALXN1910

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Enzyme replacement

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alkaline phosphatase tissue-nonspecific (ALPL)	TTMR5UV	PPBT_HUMAN	Replacement	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Alkaline phosphatase tissue-nonspecific (ALPL)	DTT	ALPL	4.67E-13	-0.15	-0.79

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05307978) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alexion